Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

SAN DIEGO, Feb. 8, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2012.

For the fourth quarter of 2012, the Company reported net income of $9.5 million, or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011. For the year ended December 31, 2012, the Company reported net income of $5.0 million, or $0.08 per fully diluted share, as compared to net income of $37.6 million, or $0.67 per fully diluted share, for 2011. One-time milestone payments of $30.0 million during 2011 were primarily responsible for the change in operating results year over year.

The Company's balance sheet at December 31, 2012 reflected total assets of $196.0 million, including cash, investments and receivables of $188.3 million compared with balances at December 31, 2011 of $138.4 million and $131.7 million, respectively.  During January 2012, the Company completed a public offering of approximately 10.9 million shares of common stock that resulted in net proceeds of approximately $83.0 million.

"During 2012 we continued to perform to financial plan and were successful in moving our VMAT2 tardive dyskinesia program forward, as well as AbbVie advancing the elagolix endometriosis and uterine fibroids programs," said Kevin C. Gorman, President and CEO of Neurocrine Biosciences. "Looking to 2013 we will have two Phase IIb readouts for our VMAT2 program, expect AbbVie to progress elagolix into Phase IIb in uterine fibroids, and we anticipate one additional program entering the clinic, resulting in a very productive year."

Revenues for the fourth quarter of 2012 were $21.9 million, compared to $11.1 million for the same period in 2011. The $10.8 million increase in revenue is primarily due to higher rev
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Dr. Gerald Zon ... acid research, recently launched a new blog in conjunction ... ( zon.trilinkbiotech.com ), focuses on what,s trending in the ... industry thought leaders, discussions of research presented at conferences ... Dr. Zon (PhD Princeton University 1971) developed ...
(Date:5/20/2013)... Md. and BALTIMORE , May 20, ... a regional private-public partnership focusing on commercializing market-relevant ... in Central Maryland , today ... as the first Entrepreneur-in-Residence (EIR) for BHI at ... Heart, Lung and Blood Institute (NHLBI). Dr. ...
(Date:5/20/2013)... BOSTON , May 20, 2013 Rhythm ... clinical trial of RM-131, the company,s novel ghrelin agonist ... diabetic patients. The trial demonstrated that RM-131 significantly accelerates ... in type 1 diabetic patients with diabetic gastroparesis. The ... conference in Orlando and recently ...
(Date:5/20/2013)... 2013 Recognizing exciting and innovative ... to its 2013 Class of Young Professors. ... provide this outstanding international group with more than ... science to meet global challenges.     , The DuPont ... young and untenured research faculty working in areas ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3
... /PRNewswire-FirstCall/ Varian, Inc. (NasdaqGS:,VARI) announced that its Board ... new director. Glover is the seventh member of ... a term expiring at the annual meeting of,the ... Vice President, Operations and Chief Financial Officer,of Anadys ...
... May 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) ... 31, 2008., Total revenues in the first quarter ... the first quarter of 2007, and included $2.0 million ... $0.6 million in patent reimbursements from Arena,s collaborations with,Merck ...
... to Provide Full Functional Validation Data for Its MISSION(R) ... ... LOUIS, May 7 Sigma-Aldrich(TM) (Nasdaq:,SIAL) and the second phase ... Consortium,s collection of approximately,160,000 previously-cloned lentiviral-based shRNA vector constructs.,Currently, more ...
Cached Biology Technology:James T. Glover Appointed to Board of Directors of Varian, Inc. 2Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 8Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries 2Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries 3
(Date:5/21/2013)... , May 21, 2013 Royal Philips ... xMATRIX, the world,s first portable ultrasound with Philips, industry ... (ICE) capability. The CX50 xMATRIX with available Live 3D ... Paris at the EuroPCR, official meeting for ... 21-24. Since its launch in 2012, Philips ...
(Date:5/21/2013)... The epigenetic modifications, which alter the way genes ... apparently be detected in the blood of pregnant ... way to foretell depression in the weeks after ... symptoms become debilitating. , The findings of the ... online in the journal Molecular Psychiatry . ...
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... Spring Harbor, NY A team of neuroscientists at Cold ... to a GPS system for locating and tracking a vital ... identification, particularly in living animals. The cells ... neurotransmitter called GABA (gamma aminobutyric acid). GABA neurons function ...
... mussels, squids as different as they may look, ... to the phylum Mollusca , also called molluscs. ... and Professor Ken Halanych, USA, with the participation of ... research into the relationships among different molluscs as part ...
... to make pest insects buzz off for good or even ... a tiny finding with enormous potential. Sujata Chaudhari, a ... the senior author of a study that was published this ... Sciences , also called PNAS. Her work includes a discovery ...
Cached Biology News:Team creates genetic 'GPS' system to comprehensively locate and track inhibitory nerve cells 2Team creates genetic 'GPS' system to comprehensively locate and track inhibitory nerve cells 3Team creates genetic 'GPS' system to comprehensively locate and track inhibitory nerve cells 4Research into molluscan phylogeny reveals deep animal relationship of snails and mussels 2Research into molluscan phylogeny reveals deep animal relationship of snails and mussels 3From protein to planes and pigskin 2From protein to planes and pigskin 3
... linear ion trap mass spectrometer enables high-throughput ... The LXQ linear ion trap mass spectrometer ... applications, delivering the fast cycle time and ... trap at an attractive price. The ...
... developed specifically for reduced mutagenicity to be ... agarose or acrylamide gels. SYBR Safe stain is ... SYBR Safe stain's detection sensitivity is better than ... as a premixed solution that can be used ...
... These are just some the things youll ... of Protein-Protein Interactions, edited by Erica Golemis, One ... skillfully edited compilation of topics in protein interaction ... text that must be a part of your ...
... This exceptionally sensitive nucleic acid gel stain ... low background in gels, making it ideal for ... standard UV transilluminators. SYBR Green I nucleic ... in capillary electrophoresis, real-time PCR assays and bandshift ...
Biology Products: